JTO Clinical and Research Reports (Apr 2021)

Trends in Molecular Testing of Lung Cancer in Mainland People’s Republic of China Over the Decade 2010 to 2019

  • Wenbin Li, PhD,
  • Yunfeng Lyu, PhD,
  • Shaoming Wang, PhD,
  • Xiaoyan Zhou, MD, PhD,
  • Jie Ma, MD,
  • Chao Xu, MS,
  • Li Fang, MS,
  • Jianming Ying, MD, PhD,
  • Lei Guo,
  • Tian Qiu,
  • Weihua Li,
  • Yan Li,
  • Nanying Che,
  • Xuefeng Bai,
  • Yanfeng Xi,
  • Yanping Hu,
  • Liping Liu,
  • Xuemei Li,
  • Shujun Zhang,
  • Hongxue Meng,
  • Xiumei Duan,
  • Yan Wu,
  • Lian He,
  • Nan Liu,
  • Jie He,
  • Hong Li,
  • Zhihui Yang,
  • Jie Lin,
  • Yi Shi,
  • Xiaoyan Li,
  • Meihong Yao,
  • Qianming Bai,
  • Ling Xie,
  • Xinghua Zhu,
  • Aiyan Xing,
  • Zebing Liu,
  • Lei Dong,
  • Wentao Huang,
  • Jie Huang,
  • Guohua Yu,
  • Xiaotong Hu,
  • Dan Su,
  • Bing Wei,
  • Fang Guo,
  • Ziguang Xu,
  • Guozhong Jiang,
  • Qian Cui,
  • Jia Li,
  • Xianhua Xu,
  • Juan Jiao,
  • Xinhui Fu,
  • Nengtai Ouyang,
  • Xiaojuan Li,
  • Xiaoying Zhu,
  • Yanjie Liu,
  • Qiushi Wang,
  • Qiong Liao,
  • Zhuo Zuo,
  • Tao Luo,
  • Chenggang Yang,
  • Xiaoming Wang,
  • Xi Liu,
  • Wenli Cui

Journal volume & issue
Vol. 2, no. 4
p. 100163

Abstract

Read online

Introduction: Lung cancer is the leading cause of cancer-related morbidity and mortality in the People’s Republic of China. Targeted therapies for patients with lung cancer, which depend on accurate identification of actionable genomic alteration, have improved survival compared with previously available treatments. However, data on the types of molecular testing often used in the People’s Republic of China, and how they have changed over time, are scarce. We explored the overall landscape of molecular testing of lung cancer in mainland People’s Republic of China in the past decade. Methods: We distributed a stratified random sampling survey of molecular testing to 49 hospitals from members of the Molecular Pathology Collaboration Group of Chinese Anti-Cancer Association which was weighted by the numbers of lung cancer cases in seven different geographic regions in mainland People’s Republic of China from 2010 to 2019. The questionnaire contained four parts for all respondents. The questionnaire ascertained the use of approved in vitro diagnostic (IVD) devices published by the Center for Medical Device Evaluation, National Medical Products Administration of the People’s Republic of China. Results: A total of 226,227 NSCLC specimens were tested from 2010 to 2019 in the selected hospitals. The annual number of initiated molecular tests increased over time (p < 0.0001), with an average annual growth rate of 31.8%. A notable increase in the number of molecular tests occurred during 2014 and 2016, which coincided with the approval of the National Medical Products Administration to IVD devices. For the diagnosis of molecular subtypes, EGFR mutation testing was first conducted in year 2007, followed by ALK translocation testing in 2010 and ROS1 in 2011. For other rare genetic variations in NSCLC, BRAF mutation testing was first launched in 2012, MET exon 14 skipping mutation in 2014, HER2 exon 20 mutations in 2017, and RET translocation in 2015. A markedly uneven distribution was also observed in the geography of leading units with the largest number of leading units located in east People’s Republic of China (34.7%, 17 of 49) and the smallest number located in northwest People’s Republic of China (6.1%, 3 of 49). The growth trends we observed illustrate the progress and increasing capability of molecular testing of lung cancer achieved in mainland People’s Republic of China in the decade from 2010. Conclusions: In the decade 2010 to 2019, progress and increased capability of molecular testing of lung cancer were achieved in mainland People’s Republic of China. Further efforts should address the clinical application of next-generation sequencing technology, rare genomic aberrations, and the balance between novel genomic testing techniques and the approval of IVD products.

Keywords